Thomas Van Loock has more than 10 years’ experience working in the field of cell therapy and vaccines manufacturing in both investigational and commercial environments.
Before joining Promethera in 2015, Thomas started his career as a consultant at GSK Vaccines where he held several positions in Quality Assurance and Validation. He then occupied Quality Assurance and deputy QP positions in proprietary or service cell therapy companies such as Cardio3 Biosciences (now renamed Celyad) and the CDMO MaSTherCell.
Thomas was promoted to Global VP Quality Assurance & QP of Promethera Biosciences in February 2020 and is responsible for all Quality aspects within Promethera group.
He also assumes the responsibilities of Qualified Person for GMP activities and Responsible Person for GDP activities.
Thomas holds a Master degree in Pharmaceutical Sciences and a Complementary Master degree in Industrial Pharmacy from the Université Catholique de Louvain, Belgium.